Clinical Trial Update: MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MRD/risk-oriented therapy with pegylated asparaginase and lineage-targeted methotrexate in untreated Philadelphia-positive acute lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• lineage-targeted methotrexate (methotrexate)
• pegylated asparaginase (pegylated asparaginase)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Untreated Philadelphia Positive Acute Lymphoblastic Leukemia, De Novo | Phase 2 | Status: COMPLETED